Pharmaceutical Stocks Worth Watching - November 13th

Key Points

• MarketBeat identified seven pharmaceutical stocks with the sector’s highest recent dollar trading volume: Eli Lilly, Johnson & Johnson, AbbVie, Abbott Laboratories, Alnylam Pharmaceuticals, Pfizer, and Merck.
• In Friday trading, Lilly, J&J, AbbVie, Abbott, and Alnylam shares rose, while Pfizer and Merck edged lower. Lilly closed at $1,444.40, near its 12-month high of $1,460.
• Alnylam stood out for its wide 12-month trading range: shares were at $164.28, far below the period high of $479.79, despite rising $7.63 on Friday.

Eli Lilly and Company, Johnson & Johnson, AbbVie, Abbott Laboratories, Alnylam Pharmaceuticals, Pfizer, and Merck & Co., Inc. are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares in companies that research, develop, manufacture, or sell prescription and over-the-counter medicines. For investors, their value can be influenced by factors such as clinical-trial results, regulatory approvals, patent expirations, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Eli Lilly and Company stock traded up $17.12 during midday trading on Friday, hitting $1,444.40. The stock had a trading volume of 795,689 shares, compared to its average volume of 2,951,607. The stock has a market cap of $1.36 trillion, a P/E ratio of 46.88, a P/E/G ratio of 1.72 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,460.00. The business has a fifty day moving average price of $1,236.58 and a 200 day moving average price of $1,108.27. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Read Our Latest Research Report on LLY

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Shares of NYSE JNJ traded up $2.77 during mid-day trading on Friday, hitting $286.29. The company had a trading volume of 2,182,743 shares, compared to its average volume of 7,933,827. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm's 50 day simple moving average is $266.83 and its two-hundred day simple moving average is $249.54. The stock has a market cap of $689.18 billion, a price-to-earnings ratio of 43.41, a PEG ratio of 2.77 and a beta of 0.22. Johnson & Johnson has a 12 month low of $193.55 and a 12 month high of $288.11.

Read Our Latest Research Report on JNJ

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV traded up $0.29 during trading hours on Friday, reaching $294.74. 1,289,565 shares of the company's stock traded hands, compared to its average volume of 6,289,345. The firm has a market capitalization of $521.00 billion, a price-to-earnings ratio of 50.75, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie has a twelve month low of $190.75 and a twelve month high of $302.93. The business's fifty day simple moving average is $274.82 and its two-hundred day simple moving average is $240.55.

Read Our Latest Research Report on ABBV

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Shares of ABT traded up $1.61 during trading hours on Friday, hitting $108.86. 2,524,063 shares of the company were exchanged, compared to its average volume of 11,095,854. The firm has a fifty day simple moving average of $103.94 and a 200-day simple moving average of $101.74. The company has a market capitalization of $188.54 billion, a PE ratio of 40.66, a PEG ratio of 1.92 and a beta of 0.54. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00.

Read Our Latest Research Report on ABT

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Alnylam Pharmaceuticals stock traded up $7.63 during midday trading on Friday, reaching $164.28. The stock had a trading volume of 1,653,251 shares, compared to its average volume of 1,599,006. Alnylam Pharmaceuticals has a twelve month low of $149.18 and a twelve month high of $479.79. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. The firm has a market cap of $22.00 billion, a price-to-earnings ratio of 8.54 and a beta of 0.42. The firm's fifty day simple moving average is $221.24 and its two-hundred day simple moving average is $276.94.

Read Our Latest Research Report on ALNY

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

NYSE:PFE traded down $0.05 during trading hours on Friday, hitting $28.78. 9,338,627 shares of the company's stock traded hands, compared to its average volume of 39,676,059. The firm has a market cap of $164.02 billion, a P/E ratio of 41.14, a P/E/G ratio of 1.94 and a beta of 0.31. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42. The stock's fifty day moving average price is $28.80 and its two-hundred day moving average price is $26.97.

Read Our Latest Research Report on PFE

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of NYSE MRK traded down $0.27 during mid-day trading on Friday, reaching $146.68. The company had a trading volume of 1,819,285 shares, compared to its average volume of 10,533,060. The stock has a fifty day moving average of $146.25 and a two-hundred day moving average of $128.41. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. The company has a market capitalization of $361.60 billion, a price-to-earnings ratio of 151.22, a PEG ratio of 6.75 and a beta of 0.13. Merck & Co., Inc. has a 12-month low of $91.49 and a 12-month high of $156.92.

Read Our Latest Research Report on MRK

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.